asked the Secretary of State for Social Services if, pursuant to his reply to the hon. Member for Newcastle upon Tyne, East on 24th May, he will place in the Library the information on which he bases his statement that the benorylate study could be justified as a basis for obtaining clinical data.
I have placed in the Library the company Press statement, the protocols and study cards relating to the study in rheumatic disease of patient compliance and comprehension of drug treatment. These documents relate to the benorylate study on which I based my reply to my hon. Friend on 24th May.—[Vol. 950, c. 601–2.]I am advised that patient compliance is a legitimate subject for clinical investigation and as the benorylate study has a substantial element of this nature its cost is allowance as a research cost under the pharmaceutical price regulation scheme.